A share price of Zevra Therapeutics Inc [ZVRA] is currently trading at $8.91, up 2.89%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ZVRA shares have gain 14.97% over the last week, with a monthly amount glided 24.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on October 07, 2024, and set its price target to $20. On September 24, 2024, Maxim Group reiterated its Buy rating and revised its price target to $25 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $17 on September 24, 2024. Maxim Group reiterated its recommendation of a Buy and raised its price target to $18 on April 02, 2024. In a note dated March 17, 2023, Maxim Group initiated an Buy rating and provided a target price of $12 on this stock.
Zevra Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.20 and $9.76. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $8.91 at the most recent close of the market. An investor can expect a potential return of 124.47% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
Trailing Twelve Months sales for Zevra Therapeutics Inc [NASDAQ:ZVRA] were 40.59M which represents 495.65% growth. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at -1.77%, Pretax Profit Margin comes in at -1.86%, and Net Profit Margin reading is -2.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -2.01 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Zevra Therapeutics Inc [NASDAQ:ZVRA] is 3.02. As well, the Quick Ratio is 2.93, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 12.00, the price to book ratio is 11.88.
Transactions by insiders
Recent insider trading involved Watton Corey Michael, Director, that happened on Mar 28 ’25 when 300.0 shares were purchased. Director, Bode John B completed a deal on Mar 19 ’25 to buy 10000.0 shares. Meanwhile, SVP, Finance & Corp Controller Sangiovanni Timothy J. sold 3000.0 shares on Feb 13 ’25.
